ADMA Biologics Inc (ADMA) stock forecast · P/E 22, rev $238.9M
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
This ADMA forecast page states what the cached financials imply — not a price target and not a guarantee. ADMA Biologics Inc outlooks on Lician start from reported revenue and the latest filing, then you decide.
Latest reported ADMA revenue for 2026-06-30 was $238.9M. Net income was $83.2M. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
Period-over-period revenue change is not in cache for ADMA, so this page does not invent a growth rate.
ADMA currently screens at market cap $4.39B and trailing P/E 21.9. Stretching today's multiple into 2026 without a filing reason is how thin forecast pages get ignored.
When the next ADMA 10-Q or 8-K lands, this outlook should move. Until then the SEC page is the source.
Not a prediction market. For the live quote and the full model, use the ADMA stock page.
Not investment advice.